Loading...
•
Sep 30, 2020
Merck Q3 2020 Earnings Report
Announced financial results for the third quarter of 2020.
Key Takeaways
Merck reported solid third-quarter results, driven by growth in oncology and animal health, despite the negative impact of the COVID-19 pandemic. Keytruda sales grew significantly, contributing to the overall revenue increase. The company is confident in achieving solid full-year revenue growth and advancing its pipeline.
Third-quarter GAAP EPS was $1.16, and non-GAAP EPS was $1.74.
Pharmaceutical sales increased by 2% to $11.3 billion, driven by oncology and hospital acute care products.
Keytruda sales grew 21% to $3.7 billion.
Animal Health sales increased by 9% to $1.2 billion.
Revenue by Segment
Forward Guidance
Merck narrowed and raised its full-year 2020 revenue range to be between $47.6 billion and $48.6 billion. Merck narrowed and lowered its full-year 2020 GAAP EPS range to be between $4.55 and $4.65. Merck narrowed and raised its full-year 2020 non-GAAP EPS range to be between $5.91 and $6.01.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...